Alfasigma to invest up to €125m in Innovative Molecules.

Alfasigma, an international pharmaceutical company, agreed to invest up to €125m in Innovative Molecules, a drug development company. "This partnership represents a strong external validation of our differentiated approach to treating HSV infections and underscores the significant clinical and commercial potential of adibelivir. We are pleased to welcome Alfasigma as a new investor in our company, as this capital infusion will accelerate the advancement of the oral formulation of adibelivir into a Phase 2 clinical development program for patients with genital herpes," Florian Vogel, Innovative Molecules CEO.